RU2009117701A - Производные пирролидина в качестве ингибиторов iap - Google Patents

Производные пирролидина в качестве ингибиторов iap Download PDF

Info

Publication number
RU2009117701A
RU2009117701A RU2009117701/04A RU2009117701A RU2009117701A RU 2009117701 A RU2009117701 A RU 2009117701A RU 2009117701/04 A RU2009117701/04 A RU 2009117701/04A RU 2009117701 A RU2009117701 A RU 2009117701A RU 2009117701 A RU2009117701 A RU 2009117701A
Authority
RU
Russia
Prior art keywords
methylaminopropionamide
pyrrolidin
cyclohexyl
oxoethyl
alkyl
Prior art date
Application number
RU2009117701/04A
Other languages
English (en)
Russian (ru)
Inventor
Марк Г. ЧАРЕСТ (US)
Марк Г. Чарест
Кристине Сютун ЧЭНЬ (US)
Кристине Сютун Чэнь
Мин ЧЭНЬ (US)
Мин Чэнь
Чжуолян ЧЭНЬ (US)
Чжуолян Чэнь
Миао ДАЙ (US)
Миао Дай
Фэн ХЕ (US)
Фэн ХЕ
Хуаншу ЛЕЙ (US)
Хуаншу ЛЕЙ
Кристофер СТРАУБ (US)
Кристофер СТРАУБ
Руньмин Дейвид ВАН (US)
Руньмин Дейвид Ван
Лей ЗАУЭЛ (US)
Лей ЗАУЭЛ
Original Assignee
Новартис АГ (CH)
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис АГ (CH), Новартис Аг filed Critical Новартис АГ (CH)
Publication of RU2009117701A publication Critical patent/RU2009117701A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RU2009117701/04A 2006-10-12 2007-10-10 Производные пирролидина в качестве ингибиторов iap RU2009117701A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82923406P 2006-10-12 2006-10-12
US60/829,234 2006-10-12

Publications (1)

Publication Number Publication Date
RU2009117701A true RU2009117701A (ru) 2010-11-20

Family

ID=38984426

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009117701/04A RU2009117701A (ru) 2006-10-12 2007-10-10 Производные пирролидина в качестве ингибиторов iap

Country Status (11)

Country Link
US (1) US8044209B2 (enExample)
EP (1) EP2102229B1 (enExample)
JP (1) JP5190062B2 (enExample)
KR (1) KR20090065548A (enExample)
CN (1) CN101595121A (enExample)
AU (1) AU2007307763A1 (enExample)
BR (1) BRPI0719221A2 (enExample)
CA (1) CA2666112A1 (enExample)
MX (1) MX2009003834A (enExample)
RU (1) RU2009117701A (enExample)
WO (1) WO2008045905A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019420B1 (ru) 2004-12-20 2014-03-31 Дженентех, Инк. Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
CN101374829A (zh) 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
MY159563A (en) 2006-05-16 2017-01-13 Pharmascience Inc Iap bir domain binding compounds
PE20110224A1 (es) * 2006-08-02 2011-04-05 Novartis Ag PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
JP2010513561A (ja) * 2006-12-19 2010-04-30 ジェネンテック, インコーポレイテッド Iapのイミダゾピリジンインヒビター
AR066348A1 (es) 2007-04-30 2009-08-12 Genentech Inc Inhibidores de las iap
ES2882855T3 (es) 2008-05-16 2021-12-02 Dana Farber Cancer Inst Inc Inmunomodulación por inhibidores de IAP
NZ590550A (en) 2008-08-02 2013-05-31 Genentech Inc Inhibitors of Apoptosis (IAP) for treating cancer
RU2523448C2 (ru) 2008-08-04 2014-07-20 СиЭйчДиАй ФАУНДЕЙШН, Инк, Ингибиторы кинуренин-3-монооксигеназы
NZ590500A (en) * 2008-08-16 2012-06-29 Genentech Inc Azaindole inhibitors of iap
JP2012500260A (ja) * 2008-08-18 2012-01-05 イェール・ユニヴァーシティー Mifモジュレーター
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US20110034469A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Heterocyclic Compound
CA2784748A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
DK2611797T3 (en) * 2010-08-31 2017-02-13 Hanmi Science Co Ltd QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSE-INducing ACTIVITY ON CELLS
CN103261186A (zh) * 2010-12-13 2013-08-21 诺瓦提斯公司 二聚化iap抑制剂
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
JP2014094886A (ja) * 2011-02-28 2014-05-22 Nippon Chemiphar Co Ltd Gpr119作動薬
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN103841829A (zh) * 2011-07-28 2014-06-04 Chdi基金会股份有限公司 某些犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
CA2844521A1 (en) 2011-08-30 2013-03-07 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
DK2750677T3 (en) 2011-08-30 2017-07-10 Chdi Foundation Inc KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND PROCEDURES FOR USE THEREOF
NO2755614T3 (enExample) * 2012-01-03 2018-03-31
JP6321020B2 (ja) * 2012-10-19 2018-05-09 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 二環式複素環化合物およびそれらの治療での使用
GB201218862D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
JP6324976B2 (ja) * 2012-10-19 2018-05-16 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 二環式複素環化合物およびそれらの治療での使用
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
LT3083616T (lt) 2013-12-20 2021-09-10 Astex Therapeutics Limited Bicikinių heterociklų junginiai ir jų panaudojimas terapijoje
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
CR20170061A (es) 2014-07-17 2017-07-17 Chdi Foundation Inc Métodos y composiciones para el tratamiento de trastornos relacionados con vih
KR20170004160A (ko) * 2015-07-01 2017-01-11 엘지전자 주식회사 이동단말기 및 그 제어방법
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
CN114685602A (zh) 2017-11-13 2022-07-01 正大天晴药业集团股份有限公司 用作iap抑制剂的smac模拟物及其用途
EP3831811A4 (en) 2018-07-31 2022-04-20 Fimecs, Inc. HETEROCYCLIC COMPOUND
EP3936126A4 (en) * 2019-03-07 2022-12-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR
PT3967702T (pt) * 2019-05-10 2024-04-09 Chia Tai Tianqing Pharmaceutical Group Co Ltd Cristalização de miméticos de smac utilizados como inibidores de iap e método para a sua preparação
JP7764027B2 (ja) 2019-07-31 2025-11-05 ファイメクス株式会社 複素環化合物
CN112521372B (zh) * 2019-09-18 2022-07-08 南京华威医药科技集团有限公司 一种细胞凋亡蛋白抑制剂及其制备方法和用途
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02000823A (es) 2000-05-23 2002-07-30 Vertex Pharma Inhibidores de caspasa y uso de los mismos.
US20060128632A1 (en) 2002-07-02 2006-06-15 Sharma Sushil K Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
DE60324964D1 (de) 2002-07-15 2009-01-08 Univ Princeton Iap-bindende verbindungen
WO2005097791A1 (en) 2004-04-07 2005-10-20 Novartis Ag Inhibitors of iap
WO2006014361A1 (en) * 2004-07-02 2006-02-09 Genentech, Inc. Inhibitors of iap
EA019420B1 (ru) * 2004-12-20 2014-03-31 Дженентех, Инк. Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
CN101374829A (zh) * 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂

Also Published As

Publication number Publication date
EP2102229A1 (en) 2009-09-23
US20110015232A1 (en) 2011-01-20
JP2010506847A (ja) 2010-03-04
JP5190062B2 (ja) 2013-04-24
EP2102229B1 (en) 2014-03-26
AU2007307763A1 (en) 2008-04-17
BRPI0719221A2 (pt) 2014-03-18
KR20090065548A (ko) 2009-06-22
MX2009003834A (es) 2009-04-22
CA2666112A1 (en) 2008-04-17
US8044209B2 (en) 2011-10-25
WO2008045905A1 (en) 2008-04-17
CN101595121A (zh) 2009-12-02

Similar Documents

Publication Publication Date Title
RU2009117701A (ru) Производные пирролидина в качестве ингибиторов iap
RU2413727C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
RU2485115C2 (ru) Производные пиримидина в качестве ингибиторов alk-5
ES2501594T3 (es) Composición farmacéutica que contiene un modulador heterocíclico de transportadores de casete de unión a ATP
JP6342393B2 (ja) 置換型ピラゾロン化合物及び使用方法
AR087355A1 (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
ME01421B (me) 5-supstituisani derivati kinazolinona kao protivtumorska sredstva
CA3059943A1 (en) K-ras modulators
JP2008525417A5 (enExample)
PE20030007A1 (es) Inhibidores de aldosa reductasa del grupo de las piridazinonas
AR068014A1 (es) Derivados de pirimidin-2-il-amina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la cinasa.
AR057786A2 (es) Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
ZA200503841B (en) Combination administration of an indolinone with achemotherapeutic agent for cell proliferation dis orders
JP2010526800A5 (enExample)
AR054799A1 (es) Derivados de oxindol
ES2370536T3 (es) 6-oxo-1,6-dihidropirimidín-2-ils en el tratamiento de enfermedades proliferativas.
KR20190016511A (ko) 히스톤(histone) 탈아세틸화 효소 억제제를 포함하는 조합물
RU2009113691A (ru) ПРОИЗВОДНЫЕ ПИРИМИДИНА, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИНГИБИРОВАНИЯ ГИДРОЛИЗА АТФ, СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ В-КЛЕТОК, СПОСОБ ОПРЕДЕЛЕНИЯ Btk В ОБРАЗЦЕ, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ВОСПРИИМЧИВЫХ К ИНГИБИРОВАНИЮ АКТИВНОСТИ Btk И СПОСОБ ПОВЫШЕНИЯ ЧУВСТВИТЕЛЬНОСТИ РАКОВЫХ КЛЕТОК К ХИМИОТЕРАПИИ
RU2014120166A (ru) Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
PT2578571E (pt) Moduladores de transportadores de atp-binding cassette
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
MX9201365A (es) Derivados del indol novedosos, procedimientos de preparacion y medicamentos que los contienen.
RU2010101416A (ru) Профилактическое/лекарственное средство от рака
RU2008110917A (ru) ПРОИЗВОДНЫЕ 7-(2-АМИНО-1-ГИДРОКСИ-ЭТИЛ)-4-ГИДРОКСИБЕНЗОТИАЗОЛ-2(3Н)-ОНА В КАЧЕСТВЕ АГОНИСТОВ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20110314